Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia first-in-human dose-escalation study of BI 1703880 plus ezabenlimab in advanced solid tumors
jRCT2031220591Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of BI 1703880 and ezabenlimab in Nonhematologic neoplasms, sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of dose-limiting toxicities during the maximum tolerated dose evaluation period. Started Jan 2023; status: recruiting.
02
Drugs
BI 1703880ezabenlimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031220591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220591.